Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis

Angela Liu; Marina Kremyanskaya; Reza Mehrazin; Qiusheng Si; Brian D. Robinson; Melissa M. Cushing; Ronald Hoffman; Yelena Z. Ginzburg

doi:10.1002/ajh.27047

Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis

Angela Liu, Marina Kremyanskaya, Reza Mehrazin, Qiusheng Si, Brian D. Robinson, Melissa M. Cushing, Ronald Hoffman, Yelena Z. Ginzburg

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1808-1813
Number of pages	6
Journal	American Journal of Hematology
Volume	98
Issue number	11
DOIs	https://doi.org/10.1002/ajh.27047
State	Published - Nov 2023

Access to Document

10.1002/ajh.27047

Cite this

@article{d2a48c071f3c4837a0fce20d7056db4a,

title = "Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis",

author = "Angela Liu and Marina Kremyanskaya and Reza Mehrazin and Qiusheng Si and Robinson, {Brian D.} and Cushing, {Melissa M.} and Ronald Hoffman and Ginzburg, {Yelena Z.}",

note = "Funding Information: M.K. has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Incyte, and MorphoSys. R.H. received research grant funding through his institution from the following sources: Citi BioPharma Corp, Curis, Inc., Dexcel Pharma Technologies Ltd. Genentech, Kartos Therapeutics, Karyopharm Therapeutics, Inc., Kymera Therapeutics, OncoMyx Therapeutics, Novartis, Protagonist Therapeutics, Repare Therapeutics, Translational Drug Development (TD2), Turning Point Therapeutics, and the NIH/NCI. Additionally, he has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Silence Therapeutics, GlycoMimetics, Dexcel Pharma Technologies LTD, Sumitomo Pharma Oncology, and Cellenkos, Inc. Finally, he holds a share of a patent filed by Domp{\'e} farmaceutici S.p.A.; Y.Z.G. received research grant funding through his institution from the following sources: Protagonist Therapeutics, Repare Therapeutics, and the NIH/NIDDK. Additionally, she has received funding as an advisor/consultant from the following sources: Takeda, Denali, Bay Clinical, Ionis Pharmaceuticals, and Protagonist Therapeutics. The remaining authors have no conflicts to report. ",

year = "2023",

month = nov,

doi = "10.1002/ajh.27047",

language = "English",

volume = "98",

pages = "1808--1813",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis

AU - Liu, Angela

AU - Kremyanskaya, Marina

AU - Mehrazin, Reza

AU - Si, Qiusheng

AU - Robinson, Brian D.

AU - Cushing, Melissa M.

AU - Hoffman, Ronald

AU - Ginzburg, Yelena Z.

N1 - Funding Information: M.K. has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Incyte, and MorphoSys. R.H. received research grant funding through his institution from the following sources: Citi BioPharma Corp, Curis, Inc., Dexcel Pharma Technologies Ltd. Genentech, Kartos Therapeutics, Karyopharm Therapeutics, Inc., Kymera Therapeutics, OncoMyx Therapeutics, Novartis, Protagonist Therapeutics, Repare Therapeutics, Translational Drug Development (TD2), Turning Point Therapeutics, and the NIH/NCI. Additionally, he has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Silence Therapeutics, GlycoMimetics, Dexcel Pharma Technologies LTD, Sumitomo Pharma Oncology, and Cellenkos, Inc. Finally, he holds a share of a patent filed by Dompé farmaceutici S.p.A.; Y.Z.G. received research grant funding through his institution from the following sources: Protagonist Therapeutics, Repare Therapeutics, and the NIH/NIDDK. Additionally, she has received funding as an advisor/consultant from the following sources: Takeda, Denali, Bay Clinical, Ionis Pharmaceuticals, and Protagonist Therapeutics. The remaining authors have no conflicts to report.

PY - 2023/11

Y1 - 2023/11

UR - http://www.scopus.com/inward/record.url?scp=85166639122&partnerID=8YFLogxK

U2 - 10.1002/ajh.27047

DO - 10.1002/ajh.27047

M3 - Comment/debate

C2 - 37528578

AN - SCOPUS:85166639122

SN - 0361-8609

VL - 98

SP - 1808

EP - 1813

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 11

ER -